What question did this study set out to answer?

This research aims to identify prognostic subgroups and evaluate treatment outcomes for estrogen receptor low-positive metastatic breast cancer patients.

February 13, 2026Open Access

Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer

Key Points

This research aims to identify prognostic subgroups and evaluate treatment outcomes for estrogen receptor low-positive metastatic breast cancer patients.
Analyze survival data based on PR-positivity among ER low-positive patients and ER-negative patients.
Evaluate the suitability of first-line endocrine therapy in ER low-positive patients.
PR-positivity correlates with improved survival for ER low-positive patients compared to ER-negative patients.
Endocrine therapy shows promise as a viable first-line treatment for ER low-positive metastatic cases.

Abstract

PR-positivity identifies a subgroup of ER low-positive dnMBC patients with superior survival compared to ER-negative patients. First-line treatment incorporating endocrine therapy may be appropriate to consider for ER low-positive patients.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Klugman et al. (Sun,) studied this question.

synapsesocial.com/papers/698ebf1d85a1ff6a93016434 https://doi.org/https://doi.org/10.1007/s10549-025-07872-7

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AI से पूछें

Bookmark

View Full Paper